Prostate cancer - Epidemiology Forecast to 2032
DelveInsight's 'Prostate cancer - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Prostate cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Prostate cancer Understanding
The DelveInsight Prostate cancer epidemiology report gives a thorough understanding of the Prostate cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Prostate cancer in the US, Europe, and Japan. The report covers the detailed information of the Prostate cancer epidemiology scenario in seven major countries (US, EU5, and Japan).
Prostate cancer Epidemiology Perspective by DelveInsight
The Prostate cancer epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Prostate cancer epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Prostate cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Prostate cancer Detailed Epidemiology Segmentation
The Prostate cancer epidemiology covered in the report provides historical as well as forecasted Prostate cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
The DelveInsight Prostate cancer report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
- The Prostate cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Prostate cancer Epidemiology Report and Model provide an overview of the global trends of Prostate cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Prostate cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM for the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Prostate cancer
- The report provides the segmentation of the Prostate cancer epidemiology
- 11-year Forecast of Prostate cancer epidemiology
- 7MM Coverage
- Prevalent and Diagnosed Cases of Prostate cancer
- Cases of Prostate cancer by Mutation Types
- Prostate cancer Cases associated with Clinical Manifestations
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Prostate cancer?
- What are the key findings pertaining to the Prostate cancer epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of patients of Prostate cancer across the 7MM during the forecast period (2019-2032)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
- What is the disease risk, burden and unmet needs of Prostate cancer?
- What are the currently available treatments of Prostate cancer?
The Prostate cancer Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Prostate cancer market
- Quantify patient populations in the global Prostate cancer market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Prostate cancer therapeutics in each of the markets covered
- Understand the magnitude of Prostate cancer population by its epidemiology
- The Prostate cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
2. EXECUTIVE SUMMARY OF PROSTATE CANCER
3. PROSTATE CANCER: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. PATIENT JOURNEY
5. EPIDEMIOLOGY AND PATIENT POPULATION
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Prostate cancer Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
5.4.1. Prostate cancer Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Prostate cancer Epidemiology Scenario in Germany (2019- 2032)
5.5.2. France Epidemiology
5.5.2.1. Prostate cancer Epidemiology Scenario in France (2019- 2032)
5.5.3. Italy Epidemiology
5.5.3.1. Prostate cancer Epidemiology Scenario in Italy (2019- 2032)
5.5.4. Spain Epidemiology
5.5.4.1. Prostate cancer Epidemiology Scenario in Spain (2019- 2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Prostate cancer Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Prostate cancer Epidemiology Scenario in Japan (2019- 2032)
6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES
6.1. Prostate cancer Treatment and Management
6.2. Prostate cancer Treatment Algorithm
7. KOL VIEWS
8. UNMET NEEDS
9. APPENDIX
9.1. Bibliography
9.2. Report Methodology
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
*The table of contents is not exhaustive; will be provided in the final report
List of Table:
Table 1: Prostate cancer Epidemiology in 7MM (2019-2032)
Table 2: Prostate cancer Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Prostate cancer Epidemiology in the United States (2019-2032)
Table 4: Prostate cancer Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Prostate cancer Epidemiology in Germany (2019-2032)
Table 6: Prostate cancer Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Prostate cancer Epidemiology in France (2019-2032)
Table 8: Prostate cancer Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Prostate cancer Epidemiology in Italy (2019-2032)
Table 10: Prostate cancer Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Prostate cancer Epidemiology in Spain (2019-2032)
Table 12: Prostate cancer Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Prostate cancer Epidemiology in the United Kingdom (2019-2032)
Table 14: Prostate cancer Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Prostate cancer Epidemiology in Japan (2019-2032)
Table 16: Prostate cancer Diagnosed and Treatable Cases in Japan (2019-2032)
Diagnosed incident cases of prostate cancer in the eight major markets (8MM*) are projected to increase from 0.56 million cases in 2018 to 0.67 million in 2028 at an annual growth rate (AGR) of 1.94%, according to GlobalData, a leading data and analytics company.
The company’s latest report, ‘Prostate Cancer - Epidemiology Forecast Report to 2028’, states that an increase in the elderly population, as a result of increasing life expectancy, is driving the number of cases to rise.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, commented: “In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer-related death in men. In 2018, the US accounted for 30.46% of the diagnosed incident cases of prostate cancer in the 8MM, with 0.17 million cases in 2018, rising to 0.20 million in 2028."
There were 0.22 million cases of prostate cancer in the five major European markets (5EU**) in 2018, which represented 38.71% of the diagnosed incident cases, followed by Japan and China, which had 0.09 and 0.08 million diagnosed incident cases, respectively.
Manthri continued: “Italy had the lowest number of diagnosed incident cases of prostate cancer in 2018, at 0.04 million. Any change in the diagnosed incident cases of prostate cancer in the 8MM is attributable to changing population demographics in the respective markets."
GlobalData's report also found that diagnosed prevalent cases of prostate cancer in the 8MM are expected to increase from 2.34 million cases in 2018 to 2.72 million cases in 2028 at an AGR of 1.63%. This growth is partly attributed to the moderately rising trend in the incidence of prostate cancer in the 8MM, combined with changing population demographics in the next ten years.
Manthri adds: “Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in the prostate gland cells. Most prostate cancers are asymptomatic and grow very slowly. Homologous recombination deficiency (HRD) mutations, which affect the DNA repair pathway, increase a man’s risk of contracting prostate cancer.”
